Safety and efficacy of etelcalcetide, an intravenous calcimimetic, for up to 52 weeks in hemodialysis patients with secondary hyperparathyroidism: results of a post-marketing surveillance in Japan

BACKGROUND: Etelcalcetide is a second-generation calcimimetic for the management of secondary hyperparathyroidism (SHPT) in patients on dialysis. We performed a post-marketing surveillance (PMS) to obtain information on the safety and efficacy of etelcalcetide in clinical practice in Japan. METHODS:...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Exp Nephrol
Main Authors: Yokoyama, Keitaro, Fukagawa, Masafumi, Shigematsu, Takashi, Akiba, Takashi, Yoshikawa, Ken, Tsuchiya, Akira, Kuwabara, Misato, Akizawa, Tadao
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Singapore 2020
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7794109/
https://ncbi.nlm.nih.gov/pubmed/32816132
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10157-020-01936-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados